Viridian Therapeutics Inc... (VRDN)
| Bid | 13.82 |
| Market Cap | 1.13B |
| Revenue (ttm) | 302K |
| Net Income (ttm) | -269.95M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -4.51 |
| Forward PE | -3.43 |
| Analyst | Buy |
| Ask | 13.89 |
| Volume | 333,406 |
| Avg. Volume (20D) | 942,731 |
| Open | 13.45 |
| Previous Close | 13.55 |
| Day's Range | 13.29 - 13.84 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.85 |
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ...
Analyst Forecast
According to 12 analyst ratings, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 145.75% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Viridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
2 months ago · seekingalpha.com
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year WindowViridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...
